In research presented at the American Thoracic Society 2024 International Conference, Benjafield and colleagues explored the treatment of sleep-disordered breathing with adaptive sero-ventilation (ASV) in opioid users with central sleep apnea (CSA).
Treating sleep-disordered breathing with methods such as adaptive sero-ventilation (ASV) could potentially improve areas such as cognitive function and productivity in patients with central sleep apnea (CSA) using opioids, according to Adam Benjafield, PhD, vice president of medical affairs at ResMed. Benjafield also discussed the impact opioids have on patients with CSA.
In research presented at the American Thoracic Society 2024 International Conference, Benjafield and colleagues explored the treatment of sleep-disordered breathing with ASV in opioid users.
Transcript
Could initiating ASV improve other outcomes in opioid users with CSA, besides sleepiness and disease-specific quality of life? For instance, could it improve cognitive function or pain levels?
There is evidence that suggests apart from sleepiness and disease specific quality of life, which is what we specifically measured in the READ-ASV registry that other aspects that when you treat sleep disordered breathing, such as central sleep apnea, there can be improvements in cognitive function. There can be improvements in productivity and other aspects as well, by having that good quality sleep, then allows better overall health.
With the opioid crisis in the US, what insights does this registry provide on that patient group?
This is a really important point. There's not a lot of clinical literature that has been published on the topic of opioid induced central sleep apnea, and the impact of treating that central sleep apnea. What we found with this registry, this specific subgroup of patients had significant improvements in both sleepiness as well as disease specific quality of life when they had their central sleep apnea treated by adaptive servo ventilation. This highlighted that there is sometimes very difficult to manage population can get significant improvements in their quality of life by having their opioid induced central sleep apnea appropriately treated, which is what the ASV therapy is designed to do.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More